For which patients is Harvoni used?

Harvoni (ledipasvir and sofosbuvir) is used to treat patients with chronic hepatitis C virus (HCV) infection. Specifically, it's indicated for:

Adults and adolescents (12 years and older): It’s effective for those with HCV genotypes 1, 4, 5, and 6.

Patients with and without cirrhosis: It can be used for patients with mild to moderate liver disease, as well as those with compensated cirrhosis and Harvoni Price in Malaysia.

Treatment-naive and treatment-experienced patients: Harvoni can be prescribed to patients who have never received treatment before or those who have previously been treated for HCV.

The treatment is usually administered for 8 to 24 weeks, depending on the specific patient characteristics and treatment history. Always consult a healthcare provider for personalized treatment recommendations.

What is the indication for Harvoni acetate?

Harvoni (ledipasvir and sofosbuvir) is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults and pediatric patients aged 12 years and older. It is effective for:

HCV genotypes 1, 4, 5, and 6: Harvoni is particularly effective for genotype 1, which is the most common strain in the U.S.

Patients with or without cirrhosis: It can be prescribed for those with compensated liver disease, including patients with mild to moderate cirrhosis.

Treatment-naive and treatment-experienced patients: It is suitable for individuals who have never been treated or those who have previously received treatment for HCV.

The specific treatment duration typically ranges from 8 to 24 weeks, depending on factors like genotype and liver health. Always consult a healthcare provider for tailored treatment decisions.

What are the cautions of Harvoni ?

Harvoni (ledipasvir and sofosbuvir) has several cautions to consider:

Drug interactions: Harvoni can interact with other medications, particularly those that affect liver enzymes (CYP3A). It's essential to inform healthcare providers about all medications being taken.

Liver function: Patients with severe hepatic impairment should use Harvoni with caution, as its safety and efficacy in this population are not well established.

HCV resistance: Patients with specific resistance-associated substitutions (RAS) may have reduced efficacy. Genotyping may be recommended before treatment.

Pregnancy: While there is limited data, caution is advised in pregnant individuals. Effective contraception is recommended during treatment and for some time after.

Reactivation of hepatitis B: Patients with a history of hepatitis B virus (HBV) infection should be monitored for HBV reactivation.

Bradycardia: Caution is advised when using Harvoni with certain medications that can cause bradycardia (slow heart rate), as there may be additive effects.

Patients should consult their healthcare provider for a thorough evaluation and to discuss potential risks and benefits before starting Harvoni Cost.